Biotech upstart Kite Pharma made its Wall Street debut Friday, pulling off an upsized IPO on the strength of investor fervor over a novel, headline-making approach to treating cancer.
When Johnson & Johnson Innovation debuted about a year ago, R&D chief Paul Stoffels promised to build an interconnected, global operation that would sink some deep roots into the world's busiest biotech hubs. On Thursday, the group showed off just how far it had come in a short time.
Head of the Scripps Translational Science Institute Eric Topol--a distinguished cardiologist and genomic researcher--says that med tech can make medicine more transparent, as well as help patients make more informed decisions.
Johnson & Johnson Innovation has announced a slate of a dozen new deals, ranging from fresh research collaborations to new investments in a range of upstart drug and device developers--all aimed at putting the multinational pharma giant on the cutting edge of new product development.
A little more than a year ago, GlaxoSmithKline disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new biotech dubbed Navitor Pharmaceuticals, which was seeded initially by Polaris and is now coming out of stealth mode with a $23.5 million Series A and the backing of a syndicate that includes SR One, GlaxoSmithKline's venture arm.
Novartis, the industry's largest employer, is flipping units and streamlining its operation to boost margins, but the company has no plans to take its foot off the gas in R&D, keeping the pace on a $10-billion-a-year research budget with hopes of cranking out 14 blockbusters by 2018.
A new type of drug delivery vehicle from the University of Pennsylvania is made up of several membranes layered on each other to protect the drug at its core or possibly deliver a few different drugs over time.
Researchers at The Ohio State University have found that to treat brain cancer and other solid tumors, a low dose of the proteasome inhibitor bortezomib improves oncolytic viruses' ability to kill cancer cells.
Scientists at the University of California, Davis, have successfully isolated the protein that allows a meningitis-causing fungus to cross the blood-brain barrier, a breakthrough that could lead to new treatments for the condition and other brain infections.
The U.K.'s GW Pharmaceuticals saw its shares hit an all-time high after disclosing promising efficacy data for Epidiolex, a cannabinoid treatment for a rare form of epilepsy.